|
시장보고서
상품코드
1750699
비소세포 폐암 치료 시장 규모, 점유율, 동향 분석 리포트 : 유형별, 치료법별, 유통 채널별, 지역별, 부문별 예측(2025-2030년)Non-small Cell Lung Cancer Therapeutics Market Size, Share & Trends Analysis Report By Type, By Treatment, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
비소세포 폐암 치료 시장의 성장과 동향
Grand View Research, Inc.의 최신 리포트에 따르면 세계의 비소세포 폐암 치료 시장 규모는 2025-2030년에 12.71%의 CAGR을 기록하며, 2030년까지 438억 9,000만 달러에 달할 것으로 예측됩니다.
비소세포폐암 치료제(NSCLC) 시장은 예측 기간 중 큰 성장을 보일 것으로 예측됩니다. 그 배경에는 폐암 치료제의 연구개발에 대한 시장 진출기업의 높은 투자, 풍부한 파이프라인의 존재, 예측 기간 중 약물의 보급 증가 등이 있습니다.
다양한 지역에서 여러 약물의 도입이 예측 기간 중 시장을 촉진할 것으로 예측됩니다. 예를 들어 2016년 10월 FDA는 제네텍이 개발한 ALK 양성 비소세포폐암 1차 치료제인 알레센자(알렉티닙)에 대해 획기적 치료 지정(Breakthrough Therapy Designation)을 부여했습니다. 이 약은 미국, 일본, 캐나다, 홍콩, 한국, 쿠웨이트, 이스라엘에서 승인되었습니다.
Bristol-Myers Squibb Company, Orion Corporation, Merck KGaA, AstraZeneca, F. Hoffmann-La Roche, Pfizer, Inc. Ltd, Pfizer, Inc. 등이 주요 분자 파이프라인을 보유하고 있습니다.
비소세포폐암 치료 시장 보고서 하이라이트
- 흡연을 위해 담배 및 기타 제품을 소비하는 인구가 증가함에 따라 선암 부문은 2024년 43.39%의 점유율을 차지하며 시장을 장악했습니다. 편평상피암(SCC) 부문은 예측 기간 중 가장 빠른 CAGR을 나타낼 것으로 예측됩니다.
- 표적 치료 부문은 2024년 50.66%의 점유율을 차지하며 시장을 장악했습니다. 면역 요법 부문은 예측 기간 중 상당한 CAGR로 성장할 것으로 예측됩니다.
- 병원 약국 부문은 2024년 66.89%의 점유율로 시장을 장악했습니다. 약국 및 소매 약국 부문은 비소세포폐암 치료를 원하는 환자들이 소비할 수 있는 규제 승인 약물의 가용성이 증가함에 따라 예측 기간 중 높은 CAGR을 보일 것으로 예측됩니다.
- 북미 비소세포폐암(NSCLC) 치료 산업은 2024년 35.41% 시장 점유율로 세계 시장을 장악하고 있습니다. 아시아태평양의 비소세포폐암(NSCLC) 치료 산업은 폐암 발병률 증가, 종양학 의료에 대한 정부 투자, 생물제제 및 표적 의약품에 대한 접근성 확대를 위한 지역적 파트너십의 확대 등을 바탕으로 빠르게 성장하고 있습니다.
목차
제1장 조사 방법과 범위
제2장 개요
제3장 비소세포 폐암 치료 시장의 변수, 동향, 범위
- 시장의 서론/계통 전망
- 시장 규모와 성장 전망
- 시장 역학
- 시장 성장 촉진요인 분석
- 시장 성장 억제요인 분석
- 비소세포 폐암 치료 시장 분석 툴
- Porter의 산업 분석
- PESTEL 분석
- 파이프라인 분석
- 가격 분석
제4장 비소세포 폐암 치료 시장 : 유형별, 추정·동향 분석
- 부문 대시보드
- 비소세포 폐암 치료 시장 점유율(유형별, 2024년과 2030년, 100만 달러)
- 편평 상피암
- 대세포암
- 선암
- 기타
제5장 비소세포 폐암 치료 시장 : 치료법별, 추정·동향 분석
- 부문 대시보드
- 비소세포 폐암 치료 시장 점유율(치료법별, 2024년과 2030년, 100만 달러)
- 화학요법
- 표적치료
- 면역치료
- 기타
제6장 비소세포 폐암 치료 시장 : 유통 채널별, 추정·동향 분석
- 부문 대시보드
- 비소세포 폐암 치료 시장 점유율(유통 채널별, 2024년과 2030년, 100만 달러)
- 병원 약국
- 드러그스토어와 소매 약국
- 온라인 약국
제7장 비소세포 폐암 치료 시장 : 지역별, 추정·동향 분석
- 비소세포 폐암 치료 시장 점유율(지역별, 2024년과 2030년, 100만 달러)
- 북미
- 미국
- 캐나다
- 멕시코
- 유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
- 아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
- 라틴아메리카
- 브라질
- 아르헨티나
- 중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트
제8장 경쟁 구도
- 주요 시장 참여 기업에 의한 최근 동향과 영향 분석
- 기업 분류
- 기업 히트맵 분석
- 기업 개요
- F. Hoffmann-La Roche Ltd
- Mylan NV
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- Pfizer Inc.
- GSK plc
- Novartis AG
- Bayer AG
- Eli Lilly and Company
- Merck & Co., Inc
Non-small Cell Lung Cancer Therapeutics Market Growth & Trends:
The global non-small cell lung cancer therapeutics market size is expected to reach USD 43.89 billion by 2030, registering a CAGR of 12.71% from 2025 to 2030, according to a new report by Grand View Research, Inc. The non-small cell cancer therapeutics (NSCLC) market is anticipated to witness significant growth during the forecast period. This can be attributed to the high investment by market players in the research and development of lung cancer therapy, presence of a rich pipeline, and increasing penetration of drugs during the forecast period.
Introduction of several drugs in various geographical regions is likely to drive the market during the forecast period. For instance, in October 2016, the FDA granted Breakthrough Therapy Designation to Alecensa (alectinib), a drug developed by Genentech to treat ALK-positive NSCLC as a first-line treatment. The drug has been approved in the U.S., Japan, Canada, Hong Kong, South Korea, Kuwait, and Israel.
Presence of a strong pipeline of drugs for non-small cell lung cancer helps propel the market during the forecast period. Bristol-Myers Squibb Company, Orion Corporation, Merck KGaA, AstraZeneca, F. Hoffmann-La Roche Ltd, and Pfizer, Inc. have major molecules in the pipeline.
Non-small Cell Lung Cancer Therapeutics Market Report Highlights:
- The adenocarcinoma segment dominated the market in 2024 with a share of 43.39% in 2024 due to an increase in the population consuming tobacco and other products for smoking. The squamous cell carcinoma (SCC) segment is anticipated to witness the fastest CAGR over the forecast period.
- The targeted therapy segment dominated the market in 2024 with a share of 50.66% in 2024. The immunotherapy segment is expected to grow at a significant CAGR over the forecast period.
- The hospital pharmacy segment dominated the market with a share of 66.89% in 2024. The drug store and retail pharmacy segment is anticipated to witness a significant CAGR over the forecast period, owing to the increased availability of regulatory-approved drugs for consumption by patients seeking to cure NSCLC.
- North America Non-small Cell Lung Cancer (NSCLC) therapeutics industry dominated globally with a market share of 35.41% in 2024. The Non-small Cell Lung Cancer (NSCLC) therapeutics industry in Asia Pacific is witnessing rapid growth fueled by rising lung cancer incidence, government investment in oncology care, and growing regional partnerships to expand access to biologics and targeted drugs.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
- 1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. Non-small cell lung cancer therapeutics market Variables, Trends, & Scope
- 3.1. Market Introduction/Lineage Outlook
- 3.2. Market Size and Growth Prospects (USD Million)
- 3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
- 3.4. Non-small Cell Lung Cancer Therapeutics Market Analysis Tools
- 3.4.1. Porter's Analysis
- 3.4.1.1. Bargaining power of the suppliers
- 3.4.1.2. Bargaining power of the buyers
- 3.4.1.3. Threats of substitution
- 3.4.1.4. Threats from new entrants
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Economic and Social landscape
- 3.4.2.3. Technological landscape
- 3.4.2.4. Environmental landscape
- 3.4.2.5. Legal landscape
- 3.4.1. Porter's Analysis
- 3.5. Pipeline Analysis
- 3.6. Pricing Analysis
Chapter 4. Non-small Cell Lung Cancer Therapeutics Market: Type Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Non-small Cell Lung Cancer Therapeutics Market: Type Movement Analysis, USD Million, 2024 & 2030
- 4.3. Squamous Cell Carcinoma
- 4.3.1. Squamous Cell Carcinoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.4. Large Cell Carcinoma
- 4.5. Large Cell Carcinoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.6. Adenocarcinoma
- 4.6.1. Adenocarcinoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.7. Others
- 4.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Non-small Cell Lung Cancer Therapeutics Market: Treatment Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Non-small Cell Lung Cancer Therapeutics Market: Treatment Movement Analysis, USD Million, 2024 & 2030
- 5.3. Chemotherapy
- 5.3.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.4. Targeted Therapy
- 5.4.1. Targeted Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.5. Immunotherapy
- 5.5.1. Immunotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.6. Others
- 5.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Non-small Cell Lung Cancer Therapeutics Market: Distribution Channel Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Non-small Cell Lung Cancer Therapeutics Market: Distribution Channel Movement Analysis, USD Million, 2024 & 2030
- 6.3. Hospital Pharmacy
- 6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4. Drug Store and Retail Pharmacy
- 6.4.1. Drug Store and Retail Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5. Online Pharmacy
- 6.5.1. Online Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Non-small Cell Lung Cancer Therapeutics Market: Regional Estimates & Trend Analysis
- 7.1. Non-small Cell Lung Cancer Therapeutics Market Share, By Region, 2024 & 2030, USD Million
- 7.2. North America
- 7.2.1. North America Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.2. U.S.
- 7.2.2.1. U.S. Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.3. Canada
- 7.2.3.1. Canada Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.2.4. Mexico
- 7.2.4.1. Mexico Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3. Europe
- 7.3.1. Europe Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.2. UK
- 7.3.2.1. UK Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.3. Germany
- 7.3.3.1. Germany Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.4. France
- 7.3.4.1. France Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.5. Italy
- 7.3.5.1. Italy Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.6. Spain
- 7.3.6.1. Spain Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.7. Denmark
- 7.3.7.1. Denmark Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.8. Sweden
- 7.3.8.1. Sweden Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.9. Norway
- 7.3.9.1. Norway Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4. Asia Pacific
- 7.4.1. Asia Pacific Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.2. Japan
- 7.4.2.1. Japan Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. China
- 7.4.3.1. China Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. India
- 7.4.4.1. India Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.5. Australia
- 7.4.5.1. Australia Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.6. South Korea
- 7.4.6.1. South Korea Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.7. Thailand
- 7.4.7.1. Thailand Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5. Latin America
- 7.5.1. Latin America Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. Brazil
- 7.5.2.1. Brazil Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Argentina
- 7.5.3.1. Argentina Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6. Middle East and Africa
- 7.6.1. Middle East and Africa Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. South Africa
- 7.6.2.1. South Africa Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. Saudi Arabia
- 7.6.3.1. Saudi Arabia Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. UAE
- 7.6.4.1. UAE Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.5. Kuwait
- 7.6.5.1. Kuwait Non-small Cell Lung Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Recent Developments & Impact Analysis by Key Market Participants
- 8.2. Company Categorization
- 8.3. Company Heat Map Analysis
- 8.4. Company Profiles
- 8.4.1. F. Hoffmann-La Roche Ltd
- 8.4.1.1. Participant's Overview
- 8.4.1.2. Financial Performance
- 8.4.1.3. Product Benchmarking
- 8.4.1.4. Recent Developments/ Strategic Initiatives
- 8.4.2. Mylan N.V.
- 8.4.2.1. Participant's Overview
- 8.4.2.2. Financial Performance
- 8.4.2.3. Product Benchmarking
- 8.4.2.4. Recent Developments/ Strategic Initiatives
- 8.4.3. Teva Pharmaceutical Industries Ltd.
- 8.4.3.1. Participant's Overview
- 8.4.3.2. Financial Performance
- 8.4.3.3. Product Benchmarking
- 8.4.3.4. Recent Developments/ Strategic Initiatives
- 8.4.4. Sanofi
- 8.4.4.1. Participant's Overview
- 8.4.4.2. Financial Performance
- 8.4.4.3. Product Benchmarking
- 8.4.4.4. Recent Developments/ Strategic Initiatives
- 8.4.5. Pfizer Inc.
- 8.4.5.1. Participant's Overview
- 8.4.5.2. Financial Performance
- 8.4.5.3. Product Benchmarking
- 8.4.5.4. Recent Developments/ Strategic Initiatives
- 8.4.6. GSK plc
- 8.4.6.1. Participant's Overview
- 8.4.6.2. Financial Performance
- 8.4.6.3. Product Benchmarking
- 8.4.6.4. Recent Developments/ Strategic Initiatives
- 8.4.7. Novartis AG
- 8.4.7.1. Participant's Overview
- 8.4.7.2. Financial Performance
- 8.4.7.3. Product Benchmarking
- 8.4.7.4. Recent Developments/ Strategic Initiatives
- 8.4.8. Bayer AG
- 8.4.8.1. Participant's Overview
- 8.4.8.2. Financial Performance
- 8.4.8.3. Product Benchmarking
- 8.4.8.4. Recent Developments/ Strategic Initiatives
- 8.4.9. Eli Lilly and Company
- 8.4.9.1. Participant's Overview
- 8.4.9.2. Financial Performance
- 8.4.9.3. Product Benchmarking
- 8.4.9.4. Recent Developments/ Strategic Initiatives
- 8.4.10. Merck & Co., Inc
- 8.4.10.1. Participant's Overview
- 8.4.10.2. Financial Performance
- 8.4.10.3. Product Benchmarking
- 8.4.10.4. Recent Developments/ Strategic Initiatives
- 8.4.1. F. Hoffmann-La Roche Ltd
